New radioimmunotherapy drug proves highly effective for killing off B cell non-Hodgkin's lymphoma

May 13, 2002

ROCHESTER, MINN. -- A Mayo Clinic study indicates the first of a new class of drugs involving radioimmunotherapy benefited a significant number of patients with low-grade B cell non-Hodgkin's lymphoma who have exhausted treatment options.

The study, published in the May 15, 2002, issue of Journal of Clinical Oncology, investigated the ability of the drug Zevalin to hone in on and kill off the non-Hodgkin's lymphoma B cells. Zevalin is the first radioimmunotherapy drug developed specifically to fight this common but usually fatal cancer of the lymph glands that, for unknown reasons, is on the increase in the United States. About 56,000 people are diagnosed with this cancer annually.

The randomized study involved 143 patients with B cell non-Hodgkin's lymphoma who had previously failed the standard chemotherapy treatments. The study found that 80 percent of patients who received Zevalin experienced a positive response in that their tumor shrunk. That compared to a 56 percent response rate in patients receiving only Rituxan, another drug used to treat the cancer.

Most noteworthy, 30 percent of the patients receiving Zevalin achieved complete remission with no evidence of the cancer present, compared to only 16 percent of patients taking Rituxan.

Radioimmunotherapy combines monoclonal antibodies, which are antibodies produced in a laboratory to react against a cancer cell, with the ability of radiation to kill off cancer cells. The mixture of radiation and antibodies is given intravenously and travels through the bloodstream to the cancer cells.

"Unlike chemotherapy which goes through the whole body, Zevalin carries the radiation payload directly to the tumor," says Thomas Witzig, M.D., a Mayo Clinic hematologist. "The drug radiates only about a five millimeter area around the tumor."

Along with its ability to hone in on cancer cells, the drug is easier on patients physically.

"One treatment is required on an outpatient basis, compared to a series of treatments with chemotherapy that can last four to six months and sometimes include hospitalization because of serious side effects," says Dr. Witzig. "There's no hair loss or prolonged fatigue, nausea or vomiting. The most significant side effect is a temporary decrease in the blood count."

Dr. Witzig and Gregory Wiseman, M.D., a Mayo Clinic nuclear medicine specialist, led the phase III research study. This study was one of several clinical trials on the drug conducted by Mayo Clinic and nine other cancer centers in the United States. The cumulative results led to the recent approval of Zevalin by the Food and Drug Administration for treatment of patients with relapsed B cell non-Hodgkin's lymphoma.
-end-
Non-Hodgkin's lymphoma ranks as the fifth most common type of cancer diagnosed in the United States. However, while incidences of most cancers have been decreasing in the past couple of decades, the number of patients diagnosed with non-Hodgkin's lymphoma has been steadily increasing.

An estimated 300,000 Americans are currently living with the disease. Most of the patients are age 40 and older. In patients aged 60 years and older, the incidence of non-Hodgkin's lymphoma is about 100 patients per 100,000 people. Zevalin is manufactured by IDEC Pharmaceuticals Corporation.

Mary Lawson
507-284-5005 (days)
507-284-2511 (evenings)
e-mail: newsbureau@mayo.edu

Video Feed: A video feed, including sound bites from the investigator and a patient and b-roll, will be fed via satellite at 2 p.m. CDT on Friday, May 10, 2002

TECHNICAL INFORMATION

Friday, May 10, 2002
Zevalin for Non-Hodgkin's Lymphoma

Eastern
Test: 15:00-15:05
Program: 15:05-15:30

Central
Test: 14:00-14:05
Program: 14:05-14:30

Satellite Coordinates

Ku-Band
Satellite: Galaxy 11
Transponder: 16 (V)
Channel: 16
Downlink Frequency: 12018 MHz
Audio: 6.2 or 6.8 MHz
Longitude: 91° W

C-Band
Satellite: Galaxy 4R
Transponder: 21 (H)
Channel: 21
Downlink Frequency: 4120 MHz
Audio: 6.2 or 6.8 MHz
Longitude: 99° W

For News Release information, please contact: 507-284-5005 (Mayo Clinic Communications)
For satellite technical questions or difficulties, contact: (800) 608-3663 (Strategic Television) or (507) 284-9118 (Mayo Clinic Satellite Desk)

Mayo Clinic

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.